Investors Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)

Share on StockTwits

Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Tuesday. $224.05 million flowed into the stock on the tick-up and $509.42 million flowed out of the stock on the tick-down, for a money net flow of $285.37 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 3rd highest net out-flow for the day. Johnson & Johnson traded up $3.20 for the day and closed at $140.75

JNJ has been the subject of several recent analyst reports. Credit Suisse Group upped their target price on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Goldman Sachs Group upgraded Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 14th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Finally, Citigroup upped their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $142.54.

The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. The company has a market cap of $367.48 billion, a P/E ratio of 19.28, a P/E/G ratio of 2.14 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. Johnson & Johnson’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.90 earnings per share. Analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a dividend of $0.90 per share. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Several large investors have recently bought and sold shares of JNJ. Partnervest Advisory Services LLC raised its position in shares of Johnson & Johnson by 6.5% in the third quarter. Partnervest Advisory Services LLC now owns 7,021 shares of the company’s stock worth $970,000 after buying an additional 428 shares in the last quarter. Ropes Wealth Advisors LLC raised its position in shares of Johnson & Johnson by 0.7% in the third quarter. Ropes Wealth Advisors LLC now owns 84,187 shares of the company’s stock worth $11,632,000 after buying an additional 603 shares in the last quarter. Dubuque Bank & Trust Co. raised its position in shares of Johnson & Johnson by 0.3% in the third quarter. Dubuque Bank & Trust Co. now owns 122,348 shares of the company’s stock worth $16,905,000 after buying an additional 419 shares in the last quarter. Dowling & Yahnke LLC raised its position in shares of Johnson & Johnson by 15.2% in the third quarter. Dowling & Yahnke LLC now owns 88,870 shares of the company’s stock worth $12,279,000 after buying an additional 11,715 shares in the last quarter. Finally, Chatham Capital Group Inc. raised its position in shares of Johnson & Johnson by 0.8% in the third quarter. Chatham Capital Group Inc. now owns 58,383 shares of the company’s stock worth $8,067,000 after buying an additional 469 shares in the last quarter. Hedge funds and other institutional investors own 66.70% of the company’s stock.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: How Do You Make Money With Penny Stocks?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply